Zobrazeno 1 - 10
of 192
pro vyhledávání: '"Michiel S. Van Der Heijden"'
Autor:
Andrea Necchi, Michiel S. Van der Heijden, Dmytro Trukhin, Avivit Peer, Howard Gurney, Boris Y. Alekseev, Francis X. Parnis, Raya Leibowitz, Maria De Santis, Petros Grivas, Jason Clark, Mihaela Munteanu, Ritesh Kataria, Calvin Jia, Arjun V. Balar, Ronald de Wit
Publikováno v:
BMC Cancer, Vol 23, Iss S1, Pp 1-11 (2024)
Abstract Background Indoleamine 2,3- dioxygenase 1 (IDO1) is an immunosuppressive enzyme that has been correlated with shorter disease-specific survival in patients with urothelial carcinoma (UC). IDO1 may counteract the antitumor effects of immune c
Externí odkaz:
https://doaj.org/article/37a2f0fcea5140a684940d22b18e5a1a
Autor:
Alberto Gil-Jimenez, Nick van Dijk, Joris L. Vos, Yoni Lubeck, Maurits L. van Montfoort, Dennis Peters, Erik Hooijberg, Annegien Broeks, Charlotte L. Zuur, Bas W. G. van Rhijn, Daniel J. Vis, Michiel S. van der Heijden, Lodewyk F. A. Wessels
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-15 (2024)
Abstract Immune checkpoint inhibitors (ICI) can achieve remarkable responses in urothelial cancer (UC), which may depend on tumor microenvironment (TME) characteristics. However, the relationship between the TME, usually characterized by immune cell
Externí odkaz:
https://doaj.org/article/a20ad317c6494fd7817047ddf7796a9d
Autor:
Maud Rijnders, J. Alberto Nakauma-González, Debbie G. J. Robbrecht, Alberto Gil-Jimenez, Hayri E. Balcioglu, Astrid A. M. Oostvogels, Maureen J. B. Aarts, Joost L. Boormans, Paul Hamberg, Michiel S. van der Heijden, Bernadett E. Szabados, Geert J. L. H. van Leenders, Niven Mehra, Jens Voortman, Hans M. Westgeest, Ronald de Wit, Astrid A. M. van der Veldt, Reno Debets, Martijn P. Lolkema
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Immune checkpoint inhibitors (ICI) improve overall survival in patients with metastatic urothelial cancer (mUC), but therapeutic success at the individual patient level varies significantly. Here we identify predictive markers of response, b
Externí odkaz:
https://doaj.org/article/5c826962a5fb45ffbb47fc08f0218098
Autor:
Lishi Lin, Aletta P. I. Houwink, Jolanda M. van Dieren, Esther K. Wolthuis, Johannes V. van Thienen, Michiel S. van der Heijden, John B. A. G. Haanen, Jos H. Beijnen, Alwin D. R. Huitema
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Introduction Severe immune‐related adverse events (irAEs) due to immune checkpoint inhibitors (ICIs) can lead to admission to the intensive care unit (ICU). In this retrospective study, we determined the incidence, treatment patterns and s
Externí odkaz:
https://doaj.org/article/b377fea45b7f46209b1c0d057520a529
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Treatment with neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy is the default treatment for muscle-invasive bladder cancer (BC). However, with the encouraging results of immune checkpoint inhibitiors (ICI) directed against PD-
Externí odkaz:
https://doaj.org/article/3b166c555ef14aaeba68efef2f1ca9c6
Autor:
Michiel S. van der Heijden, Thomas Powles, Daniel Petrylak, Ronald de Wit, Andrea Necchi, Cora N. Sternberg, Nobuaki Matsubara, Hiroyuki Nishiyama, Daniel Castellano, Syed A. Hussain, Aristotelis Bamias, Georgios Gakis, Jae-Lyun Lee, Scott T. Tagawa, Ulka Vaishampayan, Jeanny B. Aragon-Ching, Bernie J. Eigl, Rebecca R. Hozak, Erik R. Rasmussen, Meng Summer Xia, Ryan Rhodes, Sameera Wijayawardana, Katherine M. Bell-McGuinn, Amit Aggarwal, Alexandra Drakaki
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-15 (2022)
Identification of biomarkers to stratify patients who might benefit from treatment is needed to optimize targeted therapies. Here, based on an analysis of the RANGE trial (NCT02426125), the authors report potentially predictive biomarkers for surviva
Externí odkaz:
https://doaj.org/article/48cfab2e04994935a36166abe99febbf
Autor:
Sander A. L. Palit, Jeroen van Dorp, Daniel Vis, Cor Lieftink, Simon Linder, Roderick Beijersbergen, Andries M. Bergman, Wilbert Zwart, Michiel S. van der Heijden
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract Resistance to drugs targeting the androgen receptor (AR) signaling axis remains an important challenge in the treatment of prostate cancer patients. Activation of alternative growth pathways is one mechanism used by cancer cells to prolifera
Externí odkaz:
https://doaj.org/article/397d23f9500a43ac881b9b8bb5c1a817
Autor:
Lisanne F. van Dessel, Job van Riet, Minke Smits, Yanyun Zhu, Paul Hamberg, Michiel S. van der Heijden, Andries M. Bergman, Inge M. van Oort, Ronald de Wit, Emile E. Voest, Neeltje Steeghs, Takafumi N. Yamaguchi, Julie Livingstone, Paul C. Boutros, John W. M. Martens, Stefan Sleijfer, Edwin Cuppen, Wilbert Zwart, Harmen J. G. van de Werken, Niven Mehra, Martijn P. Lolkema
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-13 (2019)
Detecting genomic abnormalities in metastatic castration-resistant prostate cancer (mCRPC) may impact clinical treatment. Here, the authors present whole-genome sequencing of metastatic biopsies from 197 mCRPC patients, highlighting the landscape of
Externí odkaz:
https://doaj.org/article/f32d1b1a76f44fc6946c2d126cbc501f
Autor:
Nick van Dijk, Alberto Gil-Jimenez, Karina Silina, Maurits L. van Montfoort, Sarah Einerhand, Lars Jonkman, Charlotte S. Voskuilen, Dennis Peters, Joyce Sanders, Yoni Lubeck, Annegien Broeks, Erik Hooijberg, Daniel J. Vis, Maries van den Broek, Lodewyk F. A. Wessels, Bas W. G. van Rhijn, Michiel S. van der Heijden
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Candidate immune biomarkers have been proposed for predicting response to immunotherapy in urothelial cancer (UC). Yet, these biomarkers are imperfect and lack predictive power. A comprehensive overview of the tumor immune contexture, including Terti
Externí odkaz:
https://doaj.org/article/8fafb947107347b58fd43347731cd2e1
Autor:
Joep J. de Jong, Yang Liu, A. Gordon Robertson, Roland Seiler, Clarice S. Groeneveld, Michiel S. van der Heijden, Jonathan L. Wright, James Douglas, Marc Dall’Era, Simon J. Crabb, Bas W. G. van Rhijn, Kim E. M. van Kessel, Elai Davicioni, Mauro A. A. Castro, Yair Lotan, Ellen C. Zwarthoff, Peter C. Black, Joost L. Boormans, Ewan A. Gibb
Publikováno v:
Genome Medicine, Vol 11, Iss 1, Pp 1-13 (2019)
Abstract Background Muscle-invasive bladder cancer (MIBC) is a heterogeneous disease, and gene expression profiling has identified several molecular subtypes with distinct biological and clinicopathological characteristics. While MIBC subtyping has p
Externí odkaz:
https://doaj.org/article/f48f6e80fa2e412ea8f4dae7124976e4